{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:50:24Z","timestamp":1794019824710,"version":"4.8.0"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1038\/nrcardio.2017.51","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T10:24:25Z","timestamp":1493029465000},"page":"323-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":393,"title":["Muscle wasting and cachexia in heart failure: mechanisms and therapies"],"prefix":"10.1038","volume":"14","author":[{"given":"Stephan","family":"von Haehling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo R.","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"BFnrcardio201751_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0167-5273(02)00230-9","volume":"85","author":"W Doehner","year":"2002","unstructured":"Doehner, W. & Anker, S. D. Cardiac cachexia in early literature: a review of research prior to Medline. Int. J. Cardiol. 85, 7\u201314 (2002).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201751_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cger.2011.03.003","volume":"27","author":"IH Rosenberg","year":"2011","unstructured":"Rosenberg, I. H. Sarcopenia: origins and clinical relevance. Clin. Geriatr. Med. 27, 337\u2013339 (2011).","journal-title":"Clin. Geriatr. Med."},{"key":"BFnrcardio201751_CR3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ncpendmet0247","volume":"2","author":"J Springer","year":"2006","unstructured":"Springer, J., von Haehling, S. & Anker, S. D. The need for a standardized definition for cachexia in chronic illness. Nat. Clin. Pract. Endocrinol. Metab. 2, 416\u2013417 (2006).","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"BFnrcardio201751_CR4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S0140-6736(96)07015-8","volume":"349","author":"SD Anker","year":"1997","unstructured":"Anker, S. D.  et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050\u20131053 (1997).","journal-title":"Lancet"},{"key":"BFnrcardio201751_CR5","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0140-6736(03)12892-9","volume":"361","author":"SD Anker","year":"2003","unstructured":"Anker, S. D.  et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361, 1077\u20131083 (2003).","journal-title":"Lancet"},{"key":"BFnrcardio201751_CR6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/eurheartj\/ehw008","volume":"37","author":"M Valentova","year":"2016","unstructured":"Valentova, M.  et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. Eur. Heart J. 37, 1684\u20131691 (2016).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ejhf.240","volume":"17","author":"P Rossignol","year":"2015","unstructured":"Rossignol, P.  et al. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur. J. Heart Fail. 17, 424\u2013433 (2015).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pharmthera.2008.09.009","volume":"121","author":"S von Haehling","year":"2009","unstructured":"von Haehling, S., Lainscak, M., Springer, J. & Anker, S. D. Cardiac cachexia: a systematic overview. Pharmacol. Ther. 121, 227\u2013252 (2009).","journal-title":"Pharmacol. Ther."},{"key":"BFnrcardio201751_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1079\/PNS19920036","volume":"51","author":"KC Fearon","year":"1992","unstructured":"Fearon, K. C. The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer. Proc. Nutr. Soc. 51, 251\u2013265 (1992).","journal-title":"Proc. Nutr. Soc."},{"key":"BFnrcardio201751_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans, W. J.  et al. Cachexia: a new definition. Clin. Nutr. 27, 793\u2013799 (2008).","journal-title":"Clin. Nutr."},{"key":"BFnrcardio201751_CR11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s12020-012-9836-3","volume":"43","author":"HM Christensen","year":"2013","unstructured":"Christensen, H. M.  et al. Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine 43, 626\u2013634 (2013).","journal-title":"Endocrine"},{"key":"BFnrcardio201751_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13539-014-0164-8","volume":"5","author":"S von Haehling","year":"2014","unstructured":"von Haehling, S. & Anker, S. D. Prevalence, incidence and clinical impact of cachexia: facts and numbers \u2014 update 2014. J. Cachexia Sarcopenia Muscle 5, 261\u2013263 (2014).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijcard.2016.07.135","volume":"222","author":"T Bekfani","year":"2016","unstructured":"Bekfani, T.  et al. Sarcopenia in patients with heart failure with preserved ejection fraction: impact on muscle strength, exercise capacity and quality of life. Int. J. Cardiol. 222, 41\u201346 (2016).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201751_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/eurheartj\/ehs381","volume":"34","author":"S F\u00fclster","year":"2013","unstructured":"F\u00fclster, S.  et al. Muscle wasting in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur. Heart J. 34, 512\u2013519 (2013).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR15","first-page":"177","volume":"11","author":"V Santilli","year":"2014","unstructured":"Santilli, V., Bernetti, A., Mangone, M. & Paoloni, M. Clinical definition of sarcopenia. Clin. Cases Miner. Bone Metab. 11, 177\u2013180 (2014).","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"BFnrcardio201751_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jamda.2011.04.014","volume":"12","author":"JE Morley","year":"2011","unstructured":"Morley, J. E.  et al. Sarcopenia with limited mobility: an international consensus. J. Am. Med. Dir. Assoc. 12, 403\u2013409 (2011).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"BFnrcardio201751_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clnu.2009.12.004","volume":"29","author":"M Muscaritoli","year":"2010","unstructured":"Muscaritoli, M.  et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) \u201ccachexia-anorexia in chronic wasting diseases\u201d and \u201cnutrition in geriatrics\u201d. Clin. Nutr. 29, 154\u2013159 (2010).","journal-title":"Clin. Nutr."},{"key":"BFnrcardio201751_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jamda.2011.01.003","volume":"12","author":"RA Fielding","year":"2011","unstructured":"Fielding, R. A.  et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J. Am. Med. Dir. Assoc. 12, 249\u2013256 (2011).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"BFnrcardio201751_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft, A. J.  et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing 39, 412\u2013423 (2010).","journal-title":"Age Ageing"},{"key":"BFnrcardio201751_CR20","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/gerona\/glu013","volume":"69","author":"TT Dam","year":"2014","unstructured":"Dam, T. T.  et al. An evidence-based comparison of operational criteria for the presence of sarcopenia. J. Gerontol. A Biol. Sci. Med. Sci. 69, 584\u2013590 (2014).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"BFnrcardio201751_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13539-012-0086-2","volume":"4","author":"A Nedergaard","year":"2013","unstructured":"Nedergaard, A., Karsdal, M. A., Sun, S. & Henriksen, K. Serological muscle loss biomarkers: an overview of current concepts and future possibilities. J. Cachexia Sarcopenia Muscle 4, 1\u201317 (2013).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/jcsm.12051","volume":"6","author":"R Calvani","year":"2015","unstructured":"Calvani, R.  et al. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J. Cachexia Sarcopenia Muscle 6, 278\u2013286 (2015).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/jcsm.12082","volume":"6","author":"C Drescher","year":"2015","unstructured":"Drescher, C., Konishi, M., Ebner, N. & Springer, J. Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment. J. Cachexia Sarcopenia Muscle 6, 303\u2013311 (2015).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jcsm.12006","volume":"6","author":"Y Matsuo","year":"2015","unstructured":"Matsuo, Y.  et al. Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines. J. Cachexia Sarcopenia Muscle 6, 62\u201372 (2015).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR25","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/ejhf.400","volume":"17","author":"L Steinbeck","year":"2015","unstructured":"Steinbeck, L.  et al. Detection of muscle wasting in patients with chronic heart failure using C-terminal agrin fragment: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur. J. Heart Fail. 17, 1283\u20131293 (2015).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bmb\/ldq008","volume":"95","author":"MV Narici","year":"2010","unstructured":"Narici, M. V. & Maffulli, N. Sarcopenia: characteristics, mechanisms and functional significance. Br. Med. Bull. 95, 139\u2013159 (2010).","journal-title":"Br. Med. Bull."},{"key":"BFnrcardio201751_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s12603-009-0201-z","volume":"13","author":"G Abellan van Kan","year":"2009","unstructured":"Abellan van Kan, G. Epidemiology and consequences of sarcopenia. J. Nutr. Health Aging 13, 708\u2013712 (2009).","journal-title":"J. Nutr. Health Aging"},{"key":"BFnrcardio201751_CR28","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1152\/japplphysiol.00347.2003","volume":"95","author":"TJ Doherty","year":"2003","unstructured":"Doherty, T. J. Invited review: aging and sarcopenia. J. Appl. Physiol. 95, 1717\u20131727 (2003).","journal-title":"J. Appl. Physiol."},{"key":"BFnrcardio201751_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/13685530500277232","volume":"8","author":"JE Morley","year":"2005","unstructured":"Morley, J. E., Kim, M. J., Haren, M. T., Kevorkian, R. & Banks, W. A. Frailty and the aging male. Aging Male 8, 135\u2013140 (2005).","journal-title":"Aging Male"},{"key":"BFnrcardio201751_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s13539-014-0161-y","volume":"5","author":"JE Morley","year":"2014","unstructured":"Morley, J. E., Anker, S. D. & von Haehling, S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology \u2014 update 2014. J. Cachexia Sarcopenia Muscle 5, 253\u2013259 (2014).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13539-014-0135-0","volume":"5","author":"SD Anker","year":"2014","unstructured":"Anker, S. D.  et al. Muscle wasting disease: a proposal for a new disease classification. J. Cachexia Sarcopenia Muscle 5, 1\u20133 (2014).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejim.2015.01.008","volume":"26","author":"T Narumi","year":"2015","unstructured":"Narumi, T.  et al. Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure. Eur. J. Intern. Med. 26, 118\u2013122 (2015).","journal-title":"Eur. J. Intern. Med."},{"key":"BFnrcardio201751_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1017\/S0029665115002438","volume":"74","author":"S von Haehling","year":"2015","unstructured":"von Haehling, S. The wasting continuum in heart failure: from sarcopenia to cachexia. Proc. Nutr. Soc. 74, 367\u2013377 (2015).","journal-title":"Proc. Nutr. Soc."},{"key":"BFnrcardio201751_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1053\/euhj.1998.1446","volume":"20","author":"SD Anker","year":"1999","unstructured":"Anker, S. D.  et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur. Heart J. 20, 683\u2013693 (1999).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12603-016-0676-3","volume":"20","author":"PA Pinheiro","year":"2016","unstructured":"Pinheiro, P. A., Carneiro, J. A., Coqueiro, R. S., Pereira, R. & Fernandes, M. H. \u201cChair stand test\u201d as simple tool for sarcopenia screening in elderly women. J. Nutr. Health Aging 20, 56\u201359 (2016).","journal-title":"J. Nutr. Health Aging"},{"key":"BFnrcardio201751_CR36","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jamda.2014.04.021","volume":"15","author":"J Woo","year":"2014","unstructured":"Woo, J., Leung, J. & Morley, J. E. Validating the SARC-F: a suitable community screening tool for sarcopenia? J. Am. Med. Dir. Assoc. 15, 630\u2013634 (2014).","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"Suppl. 1","key":"BFnrcardio201751_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ggi.12197","volume":"14","author":"S Ishii","year":"2014","unstructured":"Ishii, S.  et al. Development of a simple screening test for sarcopenia in older adults. Geriatr. Gerontol. Int. 14 (Suppl. 1), 93\u2013101 (2014).","journal-title":"Geriatr. Gerontol. Int."},{"key":"BFnrcardio201751_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13539-014-0152-z","volume":"5","author":"K Josiak","year":"2014","unstructured":"Josiak, K., Jankowska, E. A., Piepoli, M. F., Banasiak, W. & Ponikowski, P. Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones. J. Cachexia Sarcopenia Muscle 5, 287\u2013296 (2014).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/jcsm.12088","volume":"6","author":"SD Anker","year":"2015","unstructured":"Anker, S. D. & Morley, J. E. Cachexia: a nutritional syndrome? J. Cachexia Sarcopenia Muscle 6, 269\u2013271 (2015).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR40","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nn.3211","volume":"15","author":"GS Yeo","year":"2012","unstructured":"Yeo, G. S. & Heisler, S. K. Unravelling the brain regulation of appetite: lessons from genetics. Nat. Neurosci. 15, 1343\u20131349 (2012).","journal-title":"Nat. Neurosci."},{"key":"BFnrcardio201751_CR41","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1210\/endo.141.11.7757","volume":"141","author":"Y Date","year":"2000","unstructured":"Date, Y.  et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141, 4255\u20134261 (2000).","journal-title":"Endocrinology"},{"key":"BFnrcardio201751_CR42","first-page":"1169","volume":"86","author":"E Arvat","year":"2001","unstructured":"Arvat, E.  et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J. Clin. Endocrinol. Metab. 86, 1169\u20131174 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrcardio201751_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/eurjhf\/hfp088","volume":"11","author":"LH Lund","year":"2009","unstructured":"Lund, L. H.  et al. Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation. Eur. J. Heart Fail. 11, 789\u2013794 (2009).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR44","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1161\/hc4201.097836","volume":"104","author":"N Nagaya","year":"2001","unstructured":"Nagaya, N.  et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic\/catabolic factors. Circulation 104, 2034\u20132038 (2001).","journal-title":"Circulation"},{"key":"BFnrcardio201751_CR45","first-page":"157","volume":"43","author":"A Stofkova","year":"2009","unstructured":"Stofkova, A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr. Regul. 43, 157\u2013168 (2009).","journal-title":"Endocr. Regul."},{"key":"BFnrcardio201751_CR46","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/35007534","volume":"404","author":"MW Schwartz","year":"2000","unstructured":"Schwartz, M. W., Woods, S. C., Porte, D. Jr, Seeley, R. J. & Baskin, D. G. Central nervous system control of food intake. Nature 404, 661\u2013671 (2000).","journal-title":"Nature"},{"key":"BFnrcardio201751_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1467-789X.2006.00270.x","volume":"8","author":"MD Klok","year":"2007","unstructured":"Klok, M. D., Jakobsdottir, S. & Drent, M. L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes. Rev. 8, 21\u201334 (2007).","journal-title":"Obes. Rev."},{"issue":"Suppl.","key":"BFnrcardio201751_CR48","first-page":"S57","volume":"43","author":"KK Ho","year":"1996","unstructured":"Ho, K. K., O'Sullivan, A. J. & Hoffman, D. M. Metabolic actions of growth hormone in man. Endocr. J. 43 (Suppl.), S57\u2013S63 (1996).","journal-title":"Endocr. J."},{"key":"BFnrcardio201751_CR49","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1172\/JCI110164","volume":"67","author":"D Rudman","year":"1981","unstructured":"Rudman, D.  et al. Impaired growth hormone secretion in the adult population: relation to age and adiposity. J. Clin. Invest. 67, 1361\u20131369 (1981).","journal-title":"J. Clin. Invest."},{"key":"BFnrcardio201751_CR50","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1210\/jcem-73-5-1081","volume":"73","author":"A Iranmanesh","year":"1991","unstructured":"Iranmanesh, A., Lizarralde, G. & Veldhuis, J. D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol. Metab. 73, 1081\u20131088 (1991).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrcardio201751_CR51","first-page":"717","volume":"19","author":"A Giustina","year":"1998","unstructured":"Giustina, A. & Veldhuis, J. D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717\u2013797 (1998).","journal-title":"Endocr. Rev."},{"key":"BFnrcardio201751_CR52","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/096374899101102","volume":"50","author":"J Tirapegui","year":"1999","unstructured":"Tirapegui, J. Effect of insulin-like growth factor-1 (IGF-1) on muscle and bone growth in experimental models. Int. J. Food Sci. Nutr. 50, 231\u2013236 (1999).","journal-title":"Int. J. Food Sci. Nutr."},{"key":"BFnrcardio201751_CR53","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","volume":"83","author":"JE Morley","year":"2006","unstructured":"Morley, J. E., Thomas, D. R. & Wilson, M. M. Cachexia: pathophysiology and clinical relevance. Am. J. Clin. Nutr. 83, 735\u2013743 (2006).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFnrcardio201751_CR54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.beem.2013.05.003","volume":"27","author":"FR Sattler","year":"2013","unstructured":"Sattler, F. R. Growth hormone in the aging male. Best Pract. Res. Clin. Endocrinol. Metab. 27, 541\u2013555 (2013).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"BFnrcardio201751_CR55","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0735-1097(01)01385-7","volume":"38","author":"SD Anker","year":"2001","unstructured":"Anker, S. D.  et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J. Am. Coll. Cardiol. 38, 443\u2013452 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201751_CR56","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1054\/jcaf.2003.23","volume":"9","author":"M Cicoira","year":"2003","unstructured":"Cicoira, M., Kalra, P. R. & Anker, S. D. Growth hormone resistance in chronic heart failure and its therapeutic implications. J. Card. Fail. 9, 219\u2013226 (2003).","journal-title":"J. Card. Fail."},{"key":"BFnrcardio201751_CR57","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1515\/bchm2.1935.233.5-6.281","volume":"233","author":"K David","year":"1935","unstructured":"David, K., Dingemanse, E., Freud, J. & Laqueur, E. \u00dcber krystallinisches m\u00e4nnliches Hormon aus Hoden (Testosteron) wirksamer als aus harn oder aus Cholesterin bereitetes Androsteron [German]. Hoppe-Seyler's Z. Physiol. Chem. 233, 281 (1935).","journal-title":"Hoppe-Seyler's Z. Physiol. Chem."},{"key":"BFnrcardio201751_CR58","first-page":"E820","volume":"269","author":"RJ Urban","year":"1995","unstructured":"Urban, R. J.  et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am. J. Physiol. 269, E820\u2013E826 (1995).","journal-title":"Am. J. Physiol."},{"key":"BFnrcardio201751_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0022-2143(99)90048-3","volume":"134","author":"RJ Urban","year":"1999","unstructured":"Urban, R. J. Effects of testosterone and growth hormone on muscle function. J. Lab. Clin. Med. 134, 7\u201310 (1999).","journal-title":"J. Lab. Clin. Med."},{"key":"BFnrcardio201751_CR60","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0195-668X(03)00083-6","volume":"24","author":"PJ Pugh","year":"2003","unstructured":"Pugh, P. J., Jones, T. H. & Channer, K. S. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur. Heart J. 24, 909\u2013915 (2003).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR61","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/hrt.2003.014639","volume":"90","author":"PJ Pugh","year":"2004","unstructured":"Pugh, P. J., Jones, R. D., West, J. N., Jones, T. H. & Channer, K. S. Testosterone treatment for men with chronic heart failure. Heart 90, 446\u2013447 (2004).","journal-title":"Heart"},{"key":"BFnrcardio201751_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/eurheartj\/ehi443","volume":"27","author":"CJ Malkin","year":"2006","unstructured":"Malkin, C. J.  et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 27, 57\u201364 (2006).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR63","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2009.04.078","volume":"54","author":"G Caminiti","year":"2009","unstructured":"Caminiti, G.  et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919\u2013927 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201751_CR64","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jacc.2010.03.090","volume":"56","author":"F Iellamo","year":"2010","unstructured":"Iellamo, F.  et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J. Am. Coll. Cardiol. 56, 1310\u20131316 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201751_CR65","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1253\/circj.CJ-12-1235","volume":"77","author":"K Okita","year":"2013","unstructured":"Okita, K., Kinugawa, S. & Tsutsui, H. Exercise intolerance in chronic heart failure \u2014 skeletal muscle dysfunction and potential therapies. Circ. J. 77, 293\u2013300 (2013).","journal-title":"Circ. J."},{"key":"BFnrcardio201751_CR66","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1136\/hrt.72.2_Suppl.S36","volume":"72","author":"AJ Coats","year":"1994","unstructured":"Coats, A. J., Clark, A. L., Piepoli, M., Volterrani, M. & Poole-Wilson, P. A. Symptoms and quality of life in heart failure: the muscle hypothesis. Br. Heart J. 72, S36\u2013S39 (1994).","journal-title":"Br. Heart J."},{"key":"BFnrcardio201751_CR67","doi-asserted-by":"publisher","first-page":"e30276","DOI":"10.1371\/journal.pone.0030276","volume":"7","author":"BM Rezk","year":"2012","unstructured":"Rezk, B. M.  et al. Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS ONE 7, e30276 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrcardio201751_CR68","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","volume":"35","author":"J Springer","year":"2014","unstructured":"Springer, J.  et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur. Heart J. 35, 932\u2013941 (2014).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s13539-012-0062-x","volume":"3","author":"FE Pedroso","year":"2012","unstructured":"Pedroso, F. E.  et al. Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia. J. Cachexia Sarcopenia Muscle 3, 199\u2013211 (2012).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR70","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijcard.2013.10.022","volume":"170","author":"Y Elkina","year":"2013","unstructured":"Elkina, Y.  et al. Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia. Int. J. Cardiol. 170, 160\u2013166 (2013).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201751_CR71","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13539-011-0035-5","volume":"2","author":"Y Elkina","year":"2011","unstructured":"Elkina, Y., von Haehling, S., Anker, S. D. & Springer, J. The role of myostatin in muscle wasting: an overview. J. Cachexia Sarcopenia Muscle 2, 143\u2013151 (2011).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR72","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/10409238.2013.857291","volume":"49","author":"MA Egerman","year":"2014","unstructured":"Egerman, M. A. & Glass, D. J. Signaling pathways controlling skeletal muscle mass. Crit. Rev. Biochem. Mol. Biol. 49, 59\u201368 (2014).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"BFnrcardio201751_CR73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2044-5040-1-4","volume":"1","author":"S Schiaffino","year":"2011","unstructured":"Schiaffino, S. & Mammucari, C. Regulation of skeletal muscle growth by the IGF1-Akt\/PKB pathway: insights from genetic models. Skelet. Muscle 1, 4 (2011).","journal-title":"Skelet. Muscle"},{"key":"BFnrcardio201751_CR74","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/ncb1101-1009","volume":"3","author":"C Rommel","year":"2001","unstructured":"Rommel, C.  et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K\/Akt\/mTOR and PI(3)K\/Akt\/GSK3 pathways. Nat. Cell Biol. 3, 1009\u20131013 (2001).","journal-title":"Nat. Cell Biol."},{"key":"BFnrcardio201751_CR75","doi-asserted-by":"publisher","first-page":"C1258","DOI":"10.1152\/ajpcell.00105.2009","volume":"296","author":"AU Trendelenburg","year":"2009","unstructured":"Trendelenburg, A. U.  et al. Myostatin reduces Akt\/TORC1\/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 296, C1258\u2013C1270 (2009).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"BFnrcardio201751_CR76","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/SPC.0b013e32834bddf9","volume":"5","author":"HQ Han","year":"2011","unstructured":"Han, H. Q. & Mitch, W. E. Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr. Opin. Support. Palliat. Care 5, 334\u2013341 (2011).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"BFnrcardio201751_CR77","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron, A. C., Lawler, A. M. & Lee, S. J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83\u201390 (1997).","journal-title":"Nature"},{"key":"BFnrcardio201751_CR78","doi-asserted-by":"publisher","first-page":"H1973","DOI":"10.1152\/ajpheart.00200.2011","volume":"300","author":"A Breitbart","year":"2011","unstructured":"Breitbart, A., Auger-Messier, M., Molkentin, J. D. & Heineke, J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am. J. Physiol. Heart Circ. Physiol. 300, H1973\u2013H1982 (2011).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrcardio201751_CR79","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/eurjhf\/hfq039","volume":"12","author":"I George","year":"2010","unstructured":"George, I.  et al. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur. J. Heart Fail. 12, 444\u2013453 (2010).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR80","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/eurjhf\/hfr024","volume":"13","author":"D Gruson","year":"2011","unstructured":"Gruson, D., Ahn, S. A., Ketelslegers, J. M. & Rousseau, M. F. Increased plasma myostatin in heart failure. Eur. J. Heart Fail. 13, 734\u2013736 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR81","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.coph.2005.01.011","volume":"5","author":"JF Tobin","year":"2005","unstructured":"Tobin, J. F. & Celeste, A. J. Myostatin, a negative regulator of muscle mass: implications for muscle degenerative diseases. Curr. Opin. Pharmacol. 5, 328\u2013332 (2005).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnrcardio201751_CR82","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/MCO.0b013e32833862df","volume":"13","author":"DJ Glass","year":"2010","unstructured":"Glass, D. J. Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care 13, 225\u2013229 (2010).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"BFnrcardio201751_CR83","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/sj.onc.1207390","volume":"23","author":"MD Marmor","year":"2004","unstructured":"Marmor, M. D. & Yarden, Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23, 2057\u20132070 (2004).","journal-title":"Oncogene"},{"key":"BFnrcardio201751_CR84","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1126\/science.2538923","volume":"243","author":"V Chau","year":"1989","unstructured":"Chau, V.  et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243, 1576\u20131583 (1989).","journal-title":"Science"},{"key":"BFnrcardio201751_CR85","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1042\/bj20040198","volume":"379","author":"LA Passmore","year":"2004","unstructured":"Passmore, L. A. & Barford, D. Getting into position: the catalytic mechanisms of protein ubiquitylation. Biochem. J. 379, 513\u2013525 (2004).","journal-title":"Biochem. J."},{"key":"BFnrcardio201751_CR86","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1126\/science.1065874","volume":"294","author":"SC Bodine","year":"2001","unstructured":"Bodine, S. C.  et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704\u20131708 (2001).","journal-title":"Science"},{"key":"BFnrcardio201751_CR87","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1113\/jphysiol.2006.118042","volume":"579","author":"ML Urso","year":"2007","unstructured":"Urso, M. L.  et al. Alterations in mRNA expression and protein products following spinal cord injury in humans. J. Physiol. 579, 877\u2013892 (2007).","journal-title":"J. Physiol."},{"key":"BFnrcardio201751_CR88","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jcsm.12034","volume":"6","author":"N Mangner","year":"2015","unstructured":"Mangner, N.  et al. Skeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragm. J. Cachexia Sarcopenia Muscle 6, 381\u2013390 (2015).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR89","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/01.mco.0000165005.01331.45","volume":"8","author":"HA Franch","year":"2005","unstructured":"Franch, H. A. & Price, S. R. Molecular signaling pathways regulating muscle proteolysis during atrophy. Curr. Opin. Clin. Nutr. Metab. Care 8, 271\u2013275 (2005).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"BFnrcardio201751_CR90","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1083\/jcb.200901052","volume":"185","author":"S Cohen","year":"2009","unstructured":"Cohen, S.  et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 185, 1083\u20131095 (2009).","journal-title":"J. Cell Biol."},{"key":"BFnrcardio201751_CR91","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1074\/jbc.M411346200","volume":"280","author":"LA Tintignac","year":"2005","unstructured":"Tintignac, L. A.  et al. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J. Biol. Chem. 280, 2847\u20132856 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrcardio201751_CR92","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/emboj.2008.52","volume":"27","author":"J Lagirand-Cantaloube","year":"2008","unstructured":"Lagirand-Cantaloube, J.  et al. The initiation factor eIF3-f is a major target for atrogin1\/MAFbx function in skeletal muscle atrophy. EMBO J. 27, 1266\u20131276 (2008).","journal-title":"EMBO J."},{"key":"BFnrcardio201751_CR93","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","volume":"119","author":"D Cai","year":"2004","unstructured":"Cai, D.  et al. IKKbeta\/NF-kappaB activation causes severe muscle wasting in mice. Cell 119, 285\u2013298 (2004).","journal-title":"Cell"},{"key":"BFnrcardio201751_CR94","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.cyto.2011.01.009","volume":"54","author":"BJ Sishi","year":"2011","unstructured":"Sishi, B. J. & Engelbrecht, A. M. Tumor necrosis factor alpha (TNF-\u03b1) inactivates the PI3-kinase\/PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine 54, 173\u2013184 (2011).","journal-title":"Cytokine"},{"key":"BFnrcardio201751_CR95","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJM199007263230405","volume":"323","author":"B Levine","year":"1990","unstructured":"Levine, B., Kalman, J., Mayer, L., Fillit, H. M. & Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236\u2013241 (1990).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201751_CR96","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1096\/fj.04-2364com","volume":"19","author":"YP Li","year":"2005","unstructured":"Li, Y. P.  et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1\/MAFbx in skeletal muscle. FASEB J. 19, 362\u2013370 (2005).","journal-title":"FASEB J."},{"key":"BFnrcardio201751_CR97","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.metabol.2013.05.018","volume":"62","author":"E Castillero","year":"2013","unstructured":"Castillero, E., Alamdari, N., Lecker, S. H. & Hasselgren, P. O. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes. Metabolism 62, 1495\u20131502 (2013).","journal-title":"Metabolism"},{"key":"BFnrcardio201751_CR98","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmb.2005.09.068","volume":"354","author":"E Kudryashova","year":"2005","unstructured":"Kudryashova, E., Kudryashov, D., Kramerova, I. & Spencer, M. J. Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. J. Mol. Biol. 354, 413\u2013424 (2005).","journal-title":"J. Mol. Biol."},{"key":"BFnrcardio201751_CR99","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2044-5040-3-11","volume":"3","author":"CI An","year":"2013","unstructured":"An, C. I., Ganio, E. & Hagiwara, N. Trip12, a HECT domain E3 ubiquitin ligase, targets Sox6 for proteasomal degradation and affects fiber type-specific gene expression in muscle cells. Skelet. Muscle 3, 11 (2013).","journal-title":"Skelet. Muscle"},{"key":"BFnrcardio201751_CR100","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1083\/jcb.201006098","volume":"191","author":"PK Paul","year":"2010","unstructured":"Paul, P. K.  et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol. 191, 1395\u20131411 (2010).","journal-title":"J. Cell Biol."},{"key":"BFnrcardio201751_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-5320(72)80002-9","volume":"39","author":"S Schiaffino","year":"1972","unstructured":"Schiaffino, S. & Hanzl\u00edkov\u00e1, V. Studies on the effect of denervation in developing muscle. II. The lysosomal system. J. Ultrastruct. Res. 39, 1\u201314 (1972).","journal-title":"J. Ultrastruct. Res."},{"key":"BFnrcardio201751_CR102","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/bj3600143","volume":"360","author":"C Deval","year":"2001","unstructured":"Deval, C.  et al. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem. J. 360, 143\u2013150 (2001).","journal-title":"Biochem. J."},{"key":"BFnrcardio201751_CR103","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.biocel.2013.04.023","volume":"45","author":"M Sandri","year":"2013","unstructured":"Sandri, M. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45, 2121\u20132129 (2013).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFnrcardio201751_CR104","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1242\/dmm.010389","volume":"6","author":"P Bonaldo","year":"2013","unstructured":"Bonaldo, P. & Sandri, M. Cellular and molecular mechanisms of muscle atrophy. Dis. Model. Mech. 6, 25\u201339 (2013).","journal-title":"Dis. Model. Mech."},{"key":"BFnrcardio201751_CR105","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nature16187","volume":"529","author":"L Garcia-Prat","year":"2016","unstructured":"Garcia-Prat, L.  et al. Autophagy maintains stemness by preventing senescence. Nature 529, 37\u201342 (2016).","journal-title":"Nature"},{"key":"BFnrcardio201751_CR106","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.4161\/auto.7.12.17877","volume":"7","author":"P Grumati","year":"2011","unstructured":"Grumati, P.  et al. Physical exercise stimulates autophagy in normal skeletal muscles but is detrimental for collagen VI-deficient muscles. Autophagy 7, 1415\u20131423 (2011).","journal-title":"Autophagy"},{"key":"BFnrcardio201751_CR107","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1152\/japplphysiol.00952.2011","volume":"112","author":"C Jamart","year":"2012","unstructured":"Jamart, C.  et al. Modulation of autophagy and ubiquitin-proteasome pathways during ultra-endurance running. J. Appl. Physiol. 112, 1529\u20131537 (2012).","journal-title":"J. Appl. Physiol."},{"key":"BFnrcardio201751_CR108","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4161\/auto.7.1.13044","volume":"7","author":"CD Gonzalez","year":"2011","unstructured":"Gonzalez, C. D.  et al. The emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy 7, 2\u201311 (2011).","journal-title":"Autophagy"},{"key":"BFnrcardio201751_CR109","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.20743","volume":"35","author":"JS Moylan","year":"2007","unstructured":"Moylan, J. S. & Reid, M. B. Oxidative stress, chronic disease, and muscle wasting. Muscle Nerve 35, 411\u2013429 (2007).","journal-title":"Muscle Nerve"},{"key":"BFnrcardio201751_CR110","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1007\/s00421-011-2287-3","volume":"112","author":"C Jamart","year":"2012","unstructured":"Jamart, C.  et al. Autophagy-related and autophagy-regulatory genes are induced in human muscle after ultraendurance exercise. Eur. J. Appl. Physiol. 112, 3173\u20133177 (2012).","journal-title":"Eur. J. Appl. Physiol."},{"key":"BFnrcardio201751_CR111","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.nmd.2008.04.010","volume":"18","author":"MC Malicdan","year":"2008","unstructured":"Malicdan, M. C., Noguchi, S., Nonaka, I., Saftig, P. & Nishino, I. Lysosomal myopathies: an excessive build-up in autophagosomes is too much to handle. Neuromuscul. Disord. 18, 521\u2013529 (2008).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrcardio201751_CR112","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1091\/mbc.e03-09-0704","volume":"15","author":"N Mizushima","year":"2004","unstructured":"Mizushima, N., Yamamoto, A., Matsui, M., Yoshimori, T. & Ohsumi, Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol. Biol. Cell 15, 1101\u20131111 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"BFnrcardio201751_CR113","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/jcb.23399","volume":"113","author":"AMJ Sanchez","year":"2012","unstructured":"Sanchez, A. M. J.  et al. AMPK promotes skeletal muscle autophagy through activation of forkhead FoxO3a and interaction with ULK1. J. Cell. Biochem. 113, 695\u2013710 (2012).","journal-title":"J. Cell. Biochem."},{"key":"BFnrcardio201751_CR114","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2220\/biomedres.36.383","volume":"36","author":"N Fujita","year":"2015","unstructured":"Fujita, N., Fujino, H., Sakamoto, H., Takegaki, J. & Deie, M. Time course of ubiquitin-proteasome and macroautophagy-lysosome pathways in skeletal muscle in rats with heart failure. Biomed. Res. 36, 383\u2013392 (2015).","journal-title":"Biomed. Res."},{"key":"BFnrcardio201751_CR115","doi-asserted-by":"publisher","first-page":"e85820","DOI":"10.1371\/journal.pone.0085820","volume":"9","author":"PR Jannig","year":"2014","unstructured":"Jannig, P. R.  et al. Autophagy signaling in skeletal muscle of infarcted rats. PLoS ONE 9, e85820 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrcardio201751_CR116","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0735-1097(98)00626-3","volume":"33","author":"V Adams","year":"1999","unstructured":"Adams, V.  et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. 33, 959\u2013965 (1999).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201751_CR117","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/heart.84.4.431","volume":"84","author":"G Vescovo","year":"2000","unstructured":"Vescovo, G.  et al. Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart 84, 431\u2013437 (2000).","journal-title":"Heart"},{"key":"BFnrcardio201751_CR118","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10741-015-9487-6","volume":"20","author":"T Knezevic","year":"2015","unstructured":"Knezevic, T.  et al. BAG3: a new player in the heart failure paradigm. Heart Fail. Rev. 20, 423\u2013434 (2015).","journal-title":"Heart Fail. Rev."},{"key":"BFnrcardio201751_CR119","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/01.mco.0000232902.97286.35","volume":"9","author":"G Vescovo","year":"2006","unstructured":"Vescovo, G. & Dalla Libera, L. Skeletal muscle apoptosis in experimental heart failure: the only link between inflammation and skeletal muscle wastage? Curr. Opin. Clin. Nutr. Metab. Care 9, 416\u2013422 (2006).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"BFnrcardio201751_CR120","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00007256-200535060-00002","volume":"35","author":"AJ Dirks","year":"2005","unstructured":"Dirks, A. J. & Leeuwenburgh, C. The role of apoptosis in age-related skeletal muscle atrophy. Sports Med. 35, 473\u2013483 (2005).","journal-title":"Sports Med."},{"key":"BFnrcardio201751_CR121","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1079\/PNS19950041","volume":"54","author":"E Hultman","year":"1995","unstructured":"Hultman, E. Fuel selection, muscle fibre. Proc. Nutr. Soc. 54, 107\u2013121 (1995).","journal-title":"Proc. Nutr. Soc."},{"key":"BFnrcardio201751_CR122","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3181\/00379727-206-43727","volume":"206","author":"E Carmeli","year":"1994","unstructured":"Carmeli, E. & Reznick, A. Z. The physiology and biochemistry of skeletal muscle atrophy as a function of age. Proc. Soc. Exp. Biol. Med. 206, 103\u2013113 (1994).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"BFnrcardio201751_CR123","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-201x.2001.00829.x","volume":"171","author":"JR Daugaard","year":"2001","unstructured":"Daugaard, J. R. & Richter, E. A. Relationship between muscle fibre composition, glucose transporter protein 4 and exercise training: possible consequences in non-insulin-dependent diabetes mellitus. Acta Physiol. Scand. 171, 267\u2013276 (2001).","journal-title":"Acta Physiol. Scand."},{"key":"BFnrcardio201751_CR124","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0167-5273(02)00245-0","volume":"85","author":"S von Haehling","year":"2002","unstructured":"von Haehling, S., Genth-Zotz, S., Anker, S. D. & Volk, H. D. Cachexia: a therapeutic approach beyond cytokine antagonism. Int. J. Cardiol. 85, 173\u2013183 (2002).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201751_CR125","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/jcmm.12253","volume":"18","author":"VA Voltarelli","year":"2014","unstructured":"Voltarelli, V. A.  et al. Lack of \u03b22 -adrenoceptors aggravates heart failure-induced skeletal muscle myopathy in mice. J. Cell. Mol. Med. 18, 1087\u20131097 (2014).","journal-title":"J. Cell. Mol. Med."},{"key":"BFnrcardio201751_CR126","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1152\/physrev.00028.2007","volume":"88","author":"GS Lynch","year":"2008","unstructured":"Lynch, G. S. & Ryall, J. G. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol. Rev. 88, 729\u2013767 (2008).","journal-title":"Physiol. Rev."},{"key":"BFnrcardio201751_CR127","doi-asserted-by":"publisher","first-page":"e41701","DOI":"10.1371\/journal.pone.0041701","volume":"7","author":"TF Cunha","year":"2012","unstructured":"Cunha, T. F.  et al. Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse skeletal muscle atrophy in heart failure. PLoS ONE 7, e41701 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrcardio201751_CR128","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1152\/japplphysiol.91067.2008","volume":"106","author":"AV Bacurau","year":"2009","unstructured":"Bacurau, A. V.  et al. Sympathetic hyperactivity differentially affects skeletal muscle mass in developing heart failure: role of exercise training. J. Appl. Physiol. 106, 1631\u20131640 (2009).","journal-title":"J. Appl. Physiol."},{"key":"BFnrcardio201751_CR129","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1161\/CIRCULATIONAHA.111.047381","volume":"125","author":"S Gielen","year":"2012","unstructured":"Gielen, S.  et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation 125, 2716\u20132727 (2012).","journal-title":"Circulation"},{"key":"BFnrcardio201751_CR130","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P.  et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 18, 891\u2013975 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR131","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cardfail.2016.07.001","volume":"22","author":"CW Yancy","year":"2016","unstructured":"Yancy, C. W.  et al. 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J. Card. Fail. 22, 659\u2013669 (2016).","journal-title":"J. Card. Fail."},{"key":"BFnrcardio201751_CR132","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1071-9164(03)00582-7","volume":"9","author":"K Hryniewicz","year":"2003","unstructured":"Hryniewicz, K., Androne, A. S., Hudaihed, A. & Katz, S. D. Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. J. Card. Fail. 9, 464\u2013468 (2003).","journal-title":"J. Card. Fail."},{"key":"BFnrcardio201751_CR133","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00508-016-1112-8","volume":"128","author":"M Saitoh","year":"2016","unstructured":"Saitoh, M.  et al. Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from the studies investigating co-morbidities aggravating heart failure. Wien. Klin. Wochenschr. 128, 497\u2013504 (2016).","journal-title":"Wien. Klin. Wochenschr."},{"key":"BFnrcardio201751_CR134","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi, L.  et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet 372, 1223\u20131230 (2008).","journal-title":"Lancet"},{"key":"BFnrcardio201751_CR135","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cnur.2007.10.003","volume":"43","author":"H Payne-Emerson","year":"2008","unstructured":"Payne-Emerson, H. & Lennie, T. A. Nutritional considerations in heart failure. Nurs. Clin. North Am. 43, 117\u2013132 (2008).","journal-title":"Nurs. Clin. North Am."},{"issue":"Suppl.","key":"BFnrcardio201751_CR136","first-page":"869","volume":"30","author":"A Macchi","year":"2009","unstructured":"Macchi, A.  et al. The role of essential amino acid supplementation in chronic heart failure [abstract]. Eur. Heart J. 30 (Suppl.), 869 (2009).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR137","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.cardiores.2006.08.018","volume":"73","author":"S von Haehling","year":"2007","unstructured":"von Haehling, S., Doehner, W. & Anker, S. D. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc. Res. 73, 298\u2013309 (2007).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio201751_CR138","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jchf.2015.08.007","volume":"4","author":"R Doukky","year":"2016","unstructured":"Doukky, R.  et al. Impact of dietary sodium restriction on heart failure outcomes. JACC Heart Fail. 4, 24\u201335 (2016).","journal-title":"JACC Heart Fail."},{"key":"BFnrcardio201751_CR139","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1093\/eurheartj\/ehi442","volume":"26","author":"KK Witte","year":"2005","unstructured":"Witte, K. K.  et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur. Heart J. 26, 2238\u20132244 (2005).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR140","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.healun.2006.03.005","volume":"25","author":"MR Mehra","year":"2006","unstructured":"Mehra, M. R., Lavie, C. J., Ventura, H. O. & Milani, R. V. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J. Heart Lung Transplant. 25, 834\u2013838 (2006).","journal-title":"J. Heart Lung Transplant."},{"key":"BFnrcardio201751_CR141","doi-asserted-by":"publisher","first-page":"111E","DOI":"10.1016\/j.amjcard.2008.03.009","volume":"101","author":"R Scognamiglio","year":"2008","unstructured":"Scognamiglio, R.  et al. Effects of oral amino acid supplements on cardiac function and remodeling in patients with type 2 diabetes with mild-to-moderate left ventricular dysfunction. Am. J. Cardiol. 101, 111E\u2013115E (2008).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio201751_CR142","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00726-014-1752-9","volume":"46","author":"H Liu","year":"2014","unstructured":"Liu, H.  et al. Leucine facilitates the insulin-stimulated glucose uptake and insulin signaling in skeletal muscle cells: involving mTORC1 and mTORC2. Amino Acids 46, 1971\u20131979 (2014).","journal-title":"Amino Acids"},{"key":"BFnrcardio201751_CR143","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.ejheart.2008.09.002","volume":"10","author":"R Aquilani","year":"2008","unstructured":"Aquilani, R.  et al. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. Eur. J. Heart Fail. 10, 1127\u20131135 (2008).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR144","doi-asserted-by":"publisher","first-page":"104E","DOI":"10.1016\/j.amjcard.2008.03.008","volume":"101","author":"R Aquilani","year":"2008","unstructured":"Aquilani, R.  et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am. J. Cardiol. 101, 104E\u2013110E (2008).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio201751_CR145","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clnu.2015.02.004","volume":"35","author":"JA Pineda-Ju\u00e1rez","year":"2016","unstructured":"Pineda-Ju\u00e1rez, J. A.  et al. Changes in body composition in heart failure patients after a resistance exercise program and branched chain amino acid supplementation. Clin. Nutr. 35, 41\u201347 (2016).","journal-title":"Clin. Nutr."},{"key":"BFnrcardio201751_CR146","first-page":"476","volume":"100","author":"MP Okoshi","year":"2013","unstructured":"Okoshi, M. P., Romeiro, F. G., Paiva, S. A. & Okoshi, K. Heart failure-induced cachexia. Arq. Bras. Cardiol. 100, 476\u2013482 (2013).","journal-title":"Arq. Bras. Cardiol."},{"key":"BFnrcardio201751_CR147","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13539-010-0008-0","volume":"1","author":"P Rozentryt","year":"2010","unstructured":"Rozentryt, P.  et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J. Cachexia Sarcopenia Muscle 1, 35\u201342 (2010).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR148","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/bmj.328.7441.711-b","volume":"328","author":"MF Piepoli","year":"2004","unstructured":"Piepoli, M. F., Davos, C., Francis, D. P., Coats, A. J. & ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 328, 189 (2004).","journal-title":"BMJ"},{"key":"BFnrcardio201751_CR149","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0735-1097(03)00848-9","volume":"42","author":"S Gielen","year":"2003","unstructured":"Gielen, S.  et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J. Am. Coll. Cardiol. 42, 861\u2013868 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201751_CR150","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.ijcard.2012.03.083","volume":"167","author":"R H\u00f6llriegel","year":"2013","unstructured":"H\u00f6llriegel, R.  et al. Anabolic effects of exercise training in patients with advanced chronic heart failure (NYHA IIIb): impact on ubiquitin-protein ligases expression and skeletal muscle size. Int. J. Cardiol. 167, 975\u2013980 (2013).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201751_CR151","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1177\/1741826711402735","volume":"19","author":"K Lenk","year":"2012","unstructured":"Lenk, K.  et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. Eur. J. Prev. Cardiol. 19, 404\u2013411 (2012).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"BFnrcardio201751_CR152","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1152\/jappl.2001.90.6.2341","volume":"90","author":"CT Pu","year":"2001","unstructured":"Pu, C. T.  et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J. Appl. Physiol. 90, 2341\u20132350 (2001).","journal-title":"J. Appl. Physiol."},{"key":"BFnrcardio201751_CR153","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ahj.2012.09.016","volume":"164","author":"M Stout","year":"2012","unstructured":"Stout, M.  et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. Am. Heart J. 164, 893\u2013901 (2012).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201751_CR154","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","volume":"357","author":"J Kjekshus","year":"2007","unstructured":"Kjekshus, J.  et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248\u20132261 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201751_CR155","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann, D. L.  et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594\u20131602 (2004).","journal-title":"Circulation"},{"key":"BFnrcardio201751_CR156","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung, E. S.  et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133\u20133140 (2003).","journal-title":"Circulation"},{"key":"BFnrcardio201751_CR157","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/sj.bjc.6602725","volume":"93","author":"PM Sanders","year":"2005","unstructured":"Sanders, P. M., Russell, S. T. & Tisdale, M. J. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer 93, 425\u2013434 (2005).","journal-title":"Br. J. Cancer"},{"key":"BFnrcardio201751_CR158","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.canlet.2005.02.007","volume":"231","author":"ST Russell","year":"2006","unstructured":"Russell, S. T., Sanders, P. M. & Tisdale, M. J. Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231, 290\u2013294 (2006).","journal-title":"Cancer Lett."},{"key":"BFnrcardio201751_CR159","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ijcard.2005.01.061","volume":"106","author":"M Lainscak","year":"2006","unstructured":"Lainscak, M., Keber, I. & Anker, S. D. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int. J. Cardiol. 106, 319\u2013322 (2006).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201751_CR160","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cardfail.2008.12.011","volume":"15","author":"EA Jankowska","year":"2009","unstructured":"Jankowska, E. A.  et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J. Card. Fail. 15, 442\u2013450 (2009).","journal-title":"J. Card. Fail."},{"key":"BFnrcardio201751_CR161","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/CIRCHEARTFAILURE.109.931063","volume":"3","author":"AL Baggish","year":"2010","unstructured":"Baggish, A. L.  et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ. Heart Fail. 3, 472\u2013476 (2010).","journal-title":"Circ. Heart Fail."},{"key":"BFnrcardio201751_CR162","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/CIRCHEARTFAILURE.111.965632","volume":"5","author":"M Toma","year":"2012","unstructured":"Toma, M.  et al. Testosterone supplementation in heart failure: a meta-analysis. Circ. Heart Fail. 5, 315\u2013321 (2012).","journal-title":"Circ. Heart Fail."},{"key":"BFnrcardio201751_CR163","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJM199603283341301","volume":"334","author":"S Fazio","year":"1996","unstructured":"Fazio, S.  et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 334, 809\u2013814 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201751_CR164","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1053\/euhj.1998.1123","volume":"19","author":"J Isgaard","year":"1998","unstructured":"Isgaard, J.  et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J. 19, 1704\u20131711 (1998).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR165","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S0140-6736(97)11329-0","volume":"351","author":"KJ Osterziel","year":"1998","unstructured":"Osterziel, K. J.  et al. Randomised, double blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351, 1233\u20131237 (1998).","journal-title":"Lancet"},{"key":"BFnrcardio201751_CR166","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1161\/01.CIR.0000149746.62908.BB","volume":"110","author":"N Nagaya","year":"2004","unstructured":"Nagaya, N.  et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 3674\u20133679 (2004).","journal-title":"Circulation"},{"key":"BFnrcardio201751_CR167","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel, J. S.  et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17, 519\u2013531 (2016).","journal-title":"Lancet Oncol."},{"key":"BFnrcardio201751_CR168","first-page":"62","volume":"5","author":"L Woodhouse","year":"2016","unstructured":"Woodhouse, L.  et al. Phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty. J. Frailty Aging 5, 62\u201370 (2016).","journal-title":"J. Frailty Aging"},{"key":"BFnrcardio201751_CR169","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","volume":"3","author":"C Becker","year":"2015","unstructured":"Becker, C.  et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 3, 948\u2013957 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"BFnrcardio201751_CR170","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.2527\/1993.71123319x","volume":"71","author":"AL Grant","year":"1993","unstructured":"Grant, A. L., Skjaerlund, D. M., Helferich, W. G., Bergen, W. G. & Merkel, R. A. Skeletal muscle growth and expression of skeletal muscle alpha-actin mRNA and insulin-like growth factor I mRNA in pigs during feeding and withdrawal of ractopamine. J. Anim. Sci. 71, 3319\u20133326 (1993).","journal-title":"J. Anim. Sci."},{"key":"BFnrcardio201751_CR171","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1476-5381.1987.tb11211.x","volume":"90","author":"NJ Rothwell","year":"1987","unstructured":"Rothwell, N. J., Stock, M. J. & Sudera, D. K. Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the beta2-adrenoceptor agonist clenbuterol. Br. J. Pharmacol. 90, 601\u2013607 (1987).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrcardio201751_CR172","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/0002-8703(85)90648-9","volume":"109","author":"B Mettauer","year":"1985","unstructured":"Mettauer, B., Rouleau, J. L. & Burgess, J. H. Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am. Heart J. 109, 840\u2013847 (1985).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201751_CR173","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0167-5273(00)00233-3","volume":"73","author":"D Harrington","year":"2000","unstructured":"Harrington, D., Chua, T. P. & Coats, A. J. The effect of salbutamol on skeletal muscle in chronic heart failure. Int. J. Cardiol. 73, 257\u2013265 (2000).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio201751_CR174","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.healun.2008.01.013","volume":"27","author":"G Kamalakkannan","year":"2008","unstructured":"Kamalakkannan, G.  et al. Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. J. Heart Lung Transplant. 27, 457\u2013461 (2008).","journal-title":"J. Heart Lung Transplant."},{"key":"BFnrcardio201751_CR175","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1517\/13543784.7.12.2043","volume":"7","author":"L Calabrese","year":"1998","unstructured":"Calabrese, L. & Resztak, K. Thalidomide revisited: pharmacology and clinical applications. Expert Opin. Investig. Drugs 7, 2043\u20132060 (1998).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnrcardio201751_CR176","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/cpt196563303","volume":"6","author":"J Sheskin","year":"1965","unstructured":"Sheskin, J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 6, 303\u2013306 (1965).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrcardio201751_CR177","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1054\/jcaf.2002.128684","volume":"8","author":"I Agoston","year":"2002","unstructured":"Agoston, I.  et al. Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J. Card. Fail. 8, 306\u2013314 (2002).","journal-title":"J. Card. Fail."},{"key":"BFnrcardio201751_CR178","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","volume":"177","author":"AL Moreira","year":"1993","unstructured":"Moreira, A. L.  et al. Thalidomide exerts its inhibitory action on tumor necrosis factor by enhancing mRNA degradation. J. Exp. Med. 177, 1675\u20131680 (1993).","journal-title":"J. Exp. Med."},{"key":"BFnrcardio201751_CR179","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1161\/CIRCULATIONAHA.105.564971","volume":"112","author":"L Gullestad","year":"2005","unstructured":"Gullestad, L.  et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 112, 3408\u20133414 (2005).","journal-title":"Circulation"},{"key":"BFnrcardio201751_CR180","first-page":"601","volume":"59","author":"A Dei Cas","year":"2011","unstructured":"Dei Cas, A., Muoio, A. & Zavaroni, I. Chronic heart failure and cachexia: role of endocrine system [Italian]. Minerva Cardioangiol. 59, 601\u2013612 (2011).","journal-title":"Minerva Cardioangiol."},{"key":"BFnrcardio201751_CR181","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/cvr\/24.2.102","volume":"24","author":"J Hulting","year":"1990","unstructured":"Hulting, J., Sollevi, A., Ullman, B., Franco-Cereceda, A. & Lundberg, J. M. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc. Res. 24, 102\u2013108 (1990).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio201751_CR182","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1677\/JOE-09-0397","volume":"206","author":"JM Scarlett","year":"2010","unstructured":"Scarlett, J. M.  et al. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure. J. Endocrinol. 206, 121\u2013130 (2010).","journal-title":"J. Endocrinol."},{"key":"BFnrcardio201751_CR183","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ejhf.82","volume":"16","author":"S Lindberg","year":"2014","unstructured":"Lindberg, S.  et al. Cardio-adipose tissue cross-talk: relationship between adiponectin, plasma pro brain natriuretic peptide and incident heart failure. Eur. J. Heart Fail. 16, 633\u2013638 (2014).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR184","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/eurjhf\/hfp046","volume":"11","author":"JP Ara\u00fajo","year":"2009","unstructured":"Ara\u00fajo, J. P., Louren\u00e7o, P., Rocha-Gon\u00e7alves, F., Ferreira, A. & Bettencourt, P. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur. J. Heart Fail. 11, 567\u2013572 (2009).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR185","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.numecd.2013.04.015","volume":"24","author":"T Szab\u00f3","year":"2014","unstructured":"Szab\u00f3, T.  et al. Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr. Metab. Cardiovasc. Dis. 24, 50\u201356 (2014).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"BFnrcardio201751_CR186","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/eurheartj\/ehm033","volume":"28","author":"MB McEntegart","year":"2007","unstructured":"McEntegart, M. B.  et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 28, 829\u2013835 (2007).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR187","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2174\/138920312803582933","volume":"13","author":"C Cabello-Verrugio","year":"2012","unstructured":"Cabello-Verrugio, C., C\u00f3rdova, G. & Salas, J. D. Angiotensin II: role in skeletal muscle atrophy. Curr. Protein Pept. Sci. 13, 560\u2013569 (2012).","journal-title":"Curr. Protein Pept. Sci."},{"key":"BFnrcardio201751_CR188","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/SPC.0000000000000030","volume":"8","author":"N Ebner","year":"2014","unstructured":"Ebner, N., Elsner, S., Springer, J. & von Haehling, S. Molecular mechanisms and treatment targets of muscle wasting and cachexia in heart failure: an overview. Curr. Opin. Support. Palliat. Care 8, 15\u201324 (2014).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"BFnrcardio201751_CR189","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/hrt.82.3.352","volume":"82","author":"DR Murdoch","year":"1999","unstructured":"Murdoch, D. R.  et al. Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Heart 82, 352\u2013356 (1999).","journal-title":"Heart"},{"key":"BFnrcardio201751_CR190","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1388-9842(02)00177-0","volume":"5","author":"PC Schulze","year":"2003","unstructured":"Schulze, P. C.  et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur. J. Heart Fail. 5, 33\u201340 (2003).","journal-title":"Eur. J. Heart Fail."},{"key":"BFnrcardio201751_CR191","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jcsm.12043","volume":"6","author":"TS Bowen","year":"2015","unstructured":"Bowen, T. S., Schuler, G. & Adams, V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J. Cachexia Sarcopenia Muscle 6, 197\u2013207 (2015).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"BFnrcardio201751_CR192","doi-asserted-by":"publisher","first-page":"40235","DOI":"10.1074\/jbc.M004356200","volume":"275","author":"M Thomas","year":"2000","unstructured":"Thomas, M.  et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J. Biol. Chem. 275, 40235\u201340243 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrcardio201751_CR193","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCRESAHA.115.304185","volume":"115","author":"N Biesemann","year":"2014","unstructured":"Biesemann, N.  et al. Myostatin regulates energy homeostasis in the heart and prevents heart failure. Circ. Res. 115, 296\u2013310 (2014).","journal-title":"Circ. Res."},{"key":"BFnrcardio201751_CR194","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","volume":"102","author":"M Rauchhaus","year":"2000","unstructured":"Rauchhaus, M.  et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102, 3060\u20133067 (2000).","journal-title":"Circulation"},{"key":"BFnrcardio201751_CR195","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/eurheartj\/ehr469","volume":"33","author":"M Sandri","year":"2012","unstructured":"Sandri, M.  et al. Age-related effects of exercise training on diastolic function in heart failure with reduced ejection fraction: the Leipzig Exercise Intervention in Chronic Heart Failure and Aging (LEICA) diastolic dysfunction study. Eur. Heart J. 33, 1758\u20131768 (2012).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201751_CR196","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/jama.2009.454","volume":"301","author":"CM O'Connor","year":"2009","unstructured":"O'Connor, C. M.  et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301, 1439\u20131450 (2009).","journal-title":"JAMA"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2017.51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2017.51","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrcardio.2017.51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2017.51.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:01:21Z","timestamp":1684468881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2017.51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,24]]},"references-count":196,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["BFnrcardio201751"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2017.51","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,24]]},"assertion":[{"value":"24 April 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.v.H. has received consulting honoraria from Chugai, Pfizer, Professional Dietetics, Respicardia, Solartium Dietetics, Sorin, Thermo Fisher Scientific, and Vifor Pharma; as well as lecture fees from Amgen and Novartis. S.D.A. has received consulting fees from Abbott Laboratories, Alere, BRAHMS GmbH, and Vifor Pharma; honoraria from Alere, BRAHMS GmbH, and Vifor Pharma; and research support from BRAHMS GmbH. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}